The available data concerning the latter topic is still speculative and preliminary, but some authors suggest that it could open a new scenario in the development of selective drugs targeting NRP1, TMPRSS2, or ACE2 in the treatment of RCC. This evidence concerns the gene ACE2 and renal cell carcinoma.